EUVIMEDEUVIMED entdecken
Crossref

Deucravacitinib Induces Proteasomal Degradation of YAP1 in Human Glioblastoma Cells

Shaonan Wang, Min Sun, Yajuan Su, Zhou Xu, Ang Li, Weiwei He

Synlett · 22.05.2024

DOI: 10.1055/a-2331-6463 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Synlett, erschienen am 22.05.2024. Verfasst von Shaonan Wang und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Deucravacitinib is a selective allosteric inhibitor of tyrosine kinase 2 (TYK2) recently approved by the FDA for the treatment of plaque psoriasis. We discovered that this compound induces proteasomal degradation of YAP1, the downstream effector of the Hippo signaling pathway, in human glioblastoma (GBM) cells (U-87 MG). This degradation is independent of the canonical Hippo pathway, which offers clues to alternative mechanisms for YAP1 regulation.

Zitieren

APA

Wang, S., Sun, M., Su, Y., Xu, Z., Li, A., & He, W. (2024). Deucravacitinib Induces Proteasomal Degradation of YAP1 in Human Glioblastoma Cells. Synlett. https://doi.org/10.1055/a-2331-6463

Vancouver

Wang S, Sun M, Su Y, Xu Z, Li A, He W. Deucravacitinib Induces Proteasomal Degradation of YAP1 in Human Glioblastoma Cells. Synlett. 2024. doi:10.1055/a-2331-6463

BibTeX
@article{Wang2024,
  author = {Wang, Shaonan and Sun, Min and Su, Yajuan and Xu, Zhou and Li, Ang and He, Weiwei},
  title = {Deucravacitinib Induces Proteasomal Degradation of YAP1 in Human Glioblastoma Cells},
  journal = {Synlett},
  year = {2024},
  doi = {10.1055/a-2331-6463}
}
Kostenlos starten →